Truist Securities Maintains Buy on Treace Medical Concepts, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Buy rating on Treace Medical Concepts (NASDAQ:TMCI) and increased the price target from $12 to $16.
December 22, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter reaffirmed a Buy rating on Treace Medical Concepts and raised the price target to $16, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence. This often results in a short-term positive impact on the stock price as the market adjusts to the new information.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100